Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Total Liabilities
Everything the company owes to creditors and other parties.
Turn Therapeutics Inc.NASDAQ: TTRX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities of $12.53M in Q1 FY2026
Q1 FY2026 total liabilities was $12.53M.
Context
- Total liabilities amounted to 67.2% of total assets at the end of Q1 FY2026.
- Total liabilities increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 7.48M USD
- Year-over-year change
- +235.8%
- 2-year CAGR
- +96.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.48M | +235.8% |
| FY2024 | 2024-12-31 | 2.23M | +15.5% |
| FY2023 | 2023-12-31 | 1.93M | — |
Total Liabilities vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 total liabilities of $12.53M is the 4th highest of the 9 companies compared; the peer median is $6.37M.
- Total liabilities amounts to 67.2% of total assets for TTRX, versus a peer median of 19.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $414.44M | -20.7% | +2.5% | 222.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $112.62M | +161.3% | +133.2% | 168.6% |
| Mar 2026 | $30.65M | -15.5% | -3.5% | 11.3% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $12.53M | — | — | 67.2% |
| Mar 2026 | $6.51M | +36.2% | +30.4% | 21.9% | |
| Mar 2026 | $6.23M | -44.5% | +11.5% | 17.2% | |
| Mar 2026 | $5.71M | -33.2% | +28.6% | 3.3% | |
| Mar 2026 | $5.24M | +263.9% | +97.2% | 49.8% | |
| Apr 2026 | $1.64M | -20.8% | -1.3% | 11.0% | |
| Peer median (excluding TTRX) | $6.37M | -18.1% | +20.1% | 19.6% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.